Market Place
Sourcing Support
Biovie Plans $20M IPO For Spinout Developing Liver Disease Drug
17 Mar 2026 //
FIERCE BIOTECH
BioVie Abstracts Accepted at 2026 ACP Meeting
12 Feb 2026 //
GLOBENEWSWIRE
Biovie To Host Live Investor Webinar And Q&a On Oct. 8
26 Sep 2025 //
GLOBENEWSWIRE
BioVie Closes $12 Million Public Offering
11 Aug 2025 //
GLOBENEWSWIRE
BioVie Adds Amy Chappell, MD, FAAN, and Kameel Farag to Board
22 Jul 2025 //
GLOBENEWSWIRE
BioVie Highlights SUNRISE-PD Trial at ATMRD Congress
26 Jun 2025 //
GLOBENEWSWIRE
BioVie to Present Phase 2 SUNRISE-PD Trial at Congress
24 Jun 2025 //
GLOBENEWSWIRE
BioVie to Host Virtual KOL Event on May 28, 2025
14 May 2025 //
GLOBENEWSWIRE
BioVie to Present Phase 2 SUNRISE-PD Trial Design at IAPRD 2025
07 May 2025 //
GLOBENEWSWIRE
BioVie to Host KOL Investor Webcast on Long COVID Treatment Lands
27 Mar 2025 //
GLOBENEWSWIRE
BioVie Inc. Prices Registered Direct Offering Under Nasdaq Rules
28 Oct 2024 //
#N/A
BioVie Closes Registered Direct Offering And Private Placement
22 Oct 2024 //
GLOBENEWSWIRE
BioVie Announces Pricing Of Direct Offering Under Nasdaq Rules
21 Oct 2024 //
GLOBENEWSWIRE
BioVie Inc. Announces Pricing of Public Offering
23 Sep 2024 //
GLOBENEWSWIRE
BioVie Secures Approvals For $12.6M Grant For COVID Trial
16 Sep 2024 //
GLOBENEWSWIRE
Privia Health Reports Second Quarter 2024 Financial Results
08 Aug 2024 //
GLOBENEWSWIRE
BioVie Inc. Announces Reverse Stock Split
06 Aug 2024 //
GLOBENEWSWIRE
BioVie Presents Protocol Design for SUNRISE-PD Trial at ATMRD 2024
25 Jun 2024 //
GLOBENEWSWIRE
BioVie To Present Phase 2 Trial Protocol For Bezisterim In Parkinson’s At ATMRD
20 Jun 2024 //
GLOBENEWSWIRE
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26
12 Jun 2024 //
GLOBENEWSWIRE
BioVie`s Bezisterim Shows Potential Sleep, Fatigue Benefits In Parkinson`s
22 May 2024 //
GLOBENEWSWIRE
BioVie: NE3107 May Restore Homeostasis In Dementia, Inflammation
18 Apr 2024 //
GLOBENEWSWIRE
BioVie Announces Pipeline Update and Near-Term Clinical Priorities
11 Mar 2024 //
GLOBENEWSWIRE
BioVie cuts `most de-risked program,` will seek partner
11 Mar 2024 //
FIERCE BIOTECH
BioVie Inc. Announces Closing of Public Offering
06 Mar 2024 //
GLOBENEWSWIRE
BioVie Inc. Announces Pricing of Public Offering
04 Mar 2024 //
GLOBENEWSWIRE
BioVie™s NE3107 Demonstrates Improvements in Motor and Non-motor Symptoms
01 Mar 2024 //
GLOBENEWSWIRE
BioVie Inc. Announces Proposed Public Offering of Common Stock
01 Mar 2024 //
GLOBENEWSWIRE
BioVie to Participate in the Oppenheimer 34th Annual Healthcare Conference
06 Feb 2024 //
GLOBENEWSWIRE
BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201
13 Nov 2023 //
GLOBENEWSWIRE
BioVie to Participate in the Truist Securities BioPharma Symposium
02 Nov 2023 //
GLOBENEWSWIRE
BioVie to Host Conference and Webcast Wednesday November 1, 2023 at 8:00 AM ET
30 Oct 2023 //
GLOBENEWSWIRE
BioVie Announces Abstract Presenting Data from Phase 2 Accepted for Presentation
26 Oct 2023 //
GLOBENEWSWIRE
Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active
25 Oct 2023 //
GLOBENEWSWIRE
BioVie to Present Blinded Data on NE3107 in the Treatment of Alzheimer™s Disease
19 Oct 2023 //
GLOBENEWSWIRE
BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 of NE3107
26 Sep 2023 //
GLOBENEWSWIRE
BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference
19 Sep 2023 //
GLOBENEWSWIRE
BioVie Presents Data Highlighting Study Population in Phase 3 Trial of NE3107
11 Sep 2023 //
GLOBENEWSWIRE
BioVie Hosting Event on NE3107 in Alzheimer`s Disease
07 Sep 2023 //
GLOBENEWSWIRE
BioVie to Host Virtual KOL Event on NE3107 in Alzheimers Disease on Sep 7, 2023
31 Aug 2023 //
GLOBENEWSWIRE
BioVie Presents Data for NE3107 at 2023 Congress of Parkinsons Disease & MD
28 Aug 2023 //
GLOBENEWSWIRE
BioVie Set to Join the Russell 2000® and Russell 3000® Indexes
23 Jun 2023 //
GLOBENEWSWIRE
BioVie To Present of NE3017 in Alzheimer™s Disease Data at 83rd Scientific
21 Jun 2023 //
GLOBENEWSWIRE
BioVie Presents Rationale for Pivotal Trial of NE3107 of Parkinsons Disease
16 May 2023 //
GLOBENEWSWIRE
BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society
20 Apr 2023 //
GLOBENEWSWIRE
BioVie Announces Data Abstracts from NE3107 Ph 2 Trials at AAN 2023
17 Apr 2023 //
GLOBENEWSWIRE
BioVie Announces Data from PII Parkinson Disease Trial Accepted for Presentation at AD
21 Mar 2023 //
GLOBENEWSWIRE
BioVie Announces Registration Details for BioVie Day" Webinar"""
14 Mar 2023 //
GLOBENEWSWIRE
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial
13 Mar 2023 //
GLOBENEWSWIRE
BioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference
09 Mar 2023 //
GLOBENEWSWIRE
BioVie Announces Additional Findings from Phase 2 Parkinson`s Disease Trial
06 Mar 2023 //
GLOBENEWSWIRE
BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107
02 Mar 2023 //
GLOBENEWSWIRE
BioVie Announces BioVie Day to be held March 23, 2023
21 Feb 2023 //
GLOBENEWSWIRE
BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
29 Dec 2022 //
PRESS RELEASE
Toni Loudenbeck of Traders News Source Interviews Cuong Do,CEO BioVie
13 Dec 2022 //
PRESS RELEASE
BioVie Issues Letter to Shareholders
07 Dec 2022 //
PRESS RELEASE
BioVie Announces Results for NE3107 in Parkinson`s & Alzheimer`s PII Trials
06 Dec 2022 //
PRESS RELEASE
BioVie Announces Additional Findings from Phase 2 Alzheimer`s Disease Trial
06 Dec 2022 //
FEEDS
BioVie Announces Positive Results for NE3107 in Parkinson &Alzheimers Ph2 Trials
05 Dec 2022 //
GLOBENEWSWIRE
BioVie’sTrial Assessing NE3107 in Alzheimer’s Disease Has Enrolled 316 Patients
29 Nov 2022 //
GLOBENEWSWIRE
